News

Viking Therapeutics to Attend Key Healthcare Conference

Viking Therapeutics to Attend Key Healthcare Conference

Viking Therapeutics to Attend Major Healthcare Conference

Viking Therapeutics, Inc. (NASDAQ: VKTX), a pioneering biopharmaceutical company based in San Diego, is set to take part in the highly anticipated Piper Sandler 37th Annual Healthcare Conference. This event, a significant milestone for those in the healthcare sector, will run from December 2-4. Although the conference is taking place in New York City, Viking’s participation reflects its dedication to advancing treatment options for metabolic and endocrine disorders.

Details of the Conference Participation

During this annual conference, the management of Viking Therapeutics will engage in various activities designed to connect with investors and stakeholders. Specifically, the team will be presenting a fireside chat and participating in individual investor meetings. The anticipated fireside chat is scheduled for December 2, from 12:30 to 12:55 p.m. Eastern Time. This will provide an excellent opportunity for attendees to learn more about the innovative developments in the field of biopharmaceuticals, particularly from Viking Therapeutics.

Innovative Focus of Viking Therapeutics

Viking Therapeutics specializes in developing groundbreaking therapies targeted at metabolic and endocrine disorders. The company is currently advancing multiple clinical programs that demonstrate its commitment to enhancing patient care through innovative pharmaceuticals. One of its flagship programs is VK2735, a novel dual agonist designed to act on both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This treatment shows promise for managing a variety of metabolic disorders.

Clinical Progress and Achievements

Clinical trials for VK2735 are underway, demonstrating a strong safety profile and favorable results in early studies. The results from Phase 1 and Phase 2 trials suggest that VK2735 not only is safe but also may offer significant clinical benefits, paving the way for a potential breakthrough in metabolic disorder treatment options. Additionally, Viking is evaluating an oral version of VK2735, further expanding its therapeutic arsenal.

Expanding its Portfolio

Alongside VK2735, Viking Therapeutics is also in the developmental stages of VK2809, an innovative oral small molecule that selectively targets thyroid hormone receptor beta. This product targets lipid and metabolic disorders and has demonstrated success in Phase 2b trials focused on non-alcoholic steatohepatitis (NASH) and fibrosis. Notably, patients treated with VK2809 showed statistically significant reductions in both LDL-C levels and liver fat compared to those receiving a placebo.

New Developments in Obesity Treatments

The company is also exploring cutting-edge dual amylin and calcitonin receptor agonists (DACRAs), aimed at addressing obesity and related metabolic disorders. These efforts underline Viking's proactive approach to tackling some of the most pressing health issues faced by patients worldwide. In the rare disease domain, Viking is advancing VK0214, another selective thyroid hormone receptor beta agonist, with initial studies indicating its safety and effectiveness in treating X-linked adrenoleukodystrophy (X-ALD).

Conclusion on Viking’s Mission

Viking Therapeutics remains committed to leveraging its expertise in metabolism to foster innovative solutions that enhance patient outcomes. As it prepares for the upcoming healthcare conference, the company looks forward to sharing insights on its ongoing research and development efforts. The work to tackle some of today's most challenging health conditions represents a meaningful part of Viking's mission and its vision for a healthier future.

Frequently Asked Questions

What is Viking Therapeutics' primary focus?

Viking Therapeutics concentrates on developing novel therapies for metabolic and endocrine disorders.

When is the Piper Sandler 37th Annual Healthcare Conference?

The conference is scheduled from December 2 to December 4.

What are some of Viking’s notable programs?

Key programs include VK2735 for metabolic disorders and VK2809 for lipid and metabolic disorders.

Where can I learn more about Viking Therapeutics?

More information can be found on the company's official website.

What is the goal of Viking's research?

The goal is to improve patient outcomes through innovative therapeutic developments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Walmart Tops 2026 Recall List: 81 Notices, Food Issues Lead

Updated Category News Views 72

Walmart Behind 81 Recalls: Scrutinizing 2026's Top Contender For an outfit that prides itself on shaking up shopping carts coast to coast, Walmart's stumble onto the recall hotseat this year is a head-scratcher. Imagine leading with 81 official recalls—that's more than a flash in the pan, it's the whole frying pan catching fire. Target and Costco aren't slouches, but...

Continue Reading
AppLovin Faces Serious Investor Lawsuit Deadline

Updated Category News Views 157

Investors' Trust Shaken: The AppLovin Controversy Well, what do we have here? Another day, another hefty lawsuit coming down the pike. The spotlight’s on AppLovin Corporation (NASDAQ: APP), where the Hagens Berman law sharks are sniffing blood in the water over what they claim are federal securities law violations. The core of this legal storm swirls around AppLovin's...

Continue Reading
Betterness Expands Health Networks with $3.5M Boost

Updated Category News Views 55

Defining a Health Revolution in the Heart of Miami Just when you think the fitness tech scene might be settling into its groove, along comes Betterness, Inc., shaking things up with another cool million in their pockets. I'm talking about their recent addition to their seed round, now sitting pretty at a robust $3.5 million. You can't ignore how they're taking a...

Continue Reading
Koppers Faces SEC Scrutiny After Earnings Miss

Updated Category News Views 124

Koppers' Third-Quarter Blues: Missing the Mark Koppers Holdings Inc. (NYSE: KOP) took a hard hit this quarter, missing Wall Street's earnings expectations by a mile. The adjusted earnings per share came in at just $0.77, while the suits down on Wall Street were expecting something closer to $1.34 to $1.37. Now, if you’re holding KOP in your portfolio, you're probably...

Continue Reading
AI-Driven Software Growth Faces Profitability Hurdles

Updated Category News Views 115

AI and Growth: A Tale of Two Strategies Is AI the superhero we’ve been waiting for, or just another fad? The KeyBanc Capital Markets' 2026 AI x Software Benchmark throws more questions into the ring than it answers. This benchmark isn't just numbers on a page; it's a pulse check on how AI is reshaping the software landscape. Seeing AI-native firms grow at a dizzying 34%...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 72

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Maritime Launch's Bold Q3 Surge Amid Space Race

Updated Category News Views 193

Rockets, Revenue, and a Bold New Path You ever hear about a spaceport tucked away in the toes of Nova Scotia, making waves with its third-quarter earnings? Well, that's exactly what's cooking over at Maritime Launch Services. These folks have managed to turn a zero into hero in a flash, reporting $5.6 million in revenue and a snug $3.5 million in net income for Q3 2026....

Continue Reading
NueSynergy Secures Top Spot in HSA Provider Rankings

Updated Category News Views 162

NueSynergy Earns its Stripes in 2026 It seems these days, healthcare costs are rising faster than you can say 'deductible.' In this chaotic landscape, a good HSA provider is worth its weight in gold. Enter NueSynergy, whose efforts have once again been acknowledged by Morningstar, a big name in the world of investment research. What Sets NueSynergy Apart? NueSynergy isn't...

Continue Reading
Where Winds Meet Celebrates 1st Anniversary With New Region

Updated Category News Views 92

A Staggering Universe Deepens: Hutuo's Introduction Just when you think you've seen it all, NetEase Games and Everstone Studio go and launch Hutuo, a compelling addition to the already sprawling universe of Where Winds Meet. On the occasion of its first global anniversary, this epic Wuxia ARPG throws players into the mud-soaked, steel-clashing chaos of a warzone, testing...

Continue Reading
Timken Maintains Robust Dividend Streak in 2026

Updated Category News Views 134

Timken Keeps Dividend Train Rolling You want to talk consistency? Timken Company just declared its quarterly dividend like clockwork. As a stockholder, that might just be your morning coffee fix before anything else. Notably, Timken's been on the NYSE since 1922, having cranked out 418 consecutive dividend payouts. That's like your grandpa never missing a Sunday golf...

Continue Reading

Top 5 Most Recently Viewed Articles

Nuix Secures Landmark Deal with German Tax Authority

Updated Category News Views 206

Nuix Partners with German Tax Authority to Enhance Investigative Processes Nuix, known for its innovative forensic analysis software, has secured a significant multiyear contract to provide its capabilities to the tax authority in Germany. This partnership with the agency in Rhineland-Palatinate marks a notable step forward in strengthening their regulatory and...

Continue Reading
reAlpha Tech Corp. Secures $2 Million in Recent Stock Offering

Updated Category News Views 237

reAlpha Tech Corp. Secures $2 Million in Recent Stock Offering reAlpha Tech Corp. (NASDAQ: AIRE), an innovative player in the AI-driven real estate technology sector, has successfully closed a public offering. This financing event, which amounted to approximately $2 million, involved the issuance of 13,333,334 shares of common stock along with accompanying warrants....

Continue Reading
OneStream Inc. Announces Participation in Major Investor Events

Updated Category News Views 133

OneStream's Upcoming Investor Conference Participation OneStream, Inc. (Nasdaq: OS), a frontrunner in enterprise finance management solutions, is set to participate in several key investor conferences. Their innovative platform revolutionizes the office of the CFO by integrating core financial and operational functions, which include financial closing, consolidation, and...

Continue Reading
SpaceX's Major Investment in xAI: A Sign of Growing AI Innovation

Updated Category News Views 335

SpaceX Makes Headlines with $2 Billion xAI Investment SpaceX has pledged a significant $2 billion investment into xAI, the artificial intelligence venture founded by Elon Musk. This funding represents a substantial portion of xAI's recent equity round, which totals $5 billion. With this undertaking, SpaceX demonstrates its unwavering support for Musk's ambitious vision of...

Continue Reading
Transforming Fishing: Innovations and Opportunities at the Fair

Updated Category News Views 319

Transforming Fishing: Innovations and Opportunities at the Fair Fishing has undergone a significant transformation in recent years, evolving from a leisurely pastime into a dynamic and technology-driven industry. The emergence of niche hobbies into mainstream activities has encouraged manufacturers to broaden their horizons. They are now appealing to a wider consumer...

Continue Reading